|Last Price||Today's Change||52-Week Range||Trading Volume|
|35.47||-1.67 (-4.50%)||30.05 - 44.95||1.1 million (Above Avg)|
Market data as of 4:00PM 04/27/15. Quotes are delayed by at least 15 min.
FDA Accepts Supplemental BLA and Grants Priority Review for ADCETRIS® (Brentuximab Vedotin) in the AETHERA Setting for the Post-Transplant Consolidation Treatment of Hodgkin Lymphoma Patients at High Risk of Relapse
04/20/2015 9:00 AM ET